Biotechnology & Life Sciences Global On demand · 24-48h

Global Biological Specimen Preservation & Handling Market Strategic Research Report

Global Biological Specimen Preservation & Handling Market St…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Biological Specimen Preservation & Handling Market
$5.48B2025
8.7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Storage Only, Sample Processing, Inventory Management, Logistics Management, Full Service, Other Services

By Application: Drug R&D, Diagnostics, Medical Training, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Azenta Life Sciences, Thermo Fisher Scientific / Patheon / PPD, Labcorp, IQVIA Laboratories, ICON plc, Medpace, Precision for Medicine, Cryoport Systems, SciSafe, Masy BioServices, Sampled, Eurofins Viracor BioPharma, Cerba Research, Clinigen, Almac Group, CellCarta, Frontage Laboratories, LabConnect, KCAS Bio, Quest Diagnostics, Charles River Laboratories, WuXi AppTec, Parexel, Sonic Clinical Trials, REPROCELL, Astoriom, Cryosite, Discovery Life Sciences, BioIVT, Boca Biolistics, Cureline

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 184 pages
Market size 2025
$5.48B
Billion USD
Forecast CAGR
8.7%
2025-2032
Forecast 2032
$9.8B
Projected
Gebieden
5
Asia Pacific · Latin America · MEA · Europe · North America

Overzicht

Scope of the Report

The global Biological Specimen Preservation & Handling market size is predicted to grow from US$ 5,478 million in 2025 to US$ 9,851 million in 2032; it is expected to grow at a CAGR of 8.7% from 2026 to 2032.

Biological sample storage and processing services refer to third-party services that manage human, animal, or microbial samples, providing end-to-end or modular workflows including sample receipt, identification registration, barcode tracking, pre-processing, aliquoting, refrigerated/frozen/ultra-low temperature/liquid nitrogen storage, inventory management, inbound and outbound logistics, transport, and eventual disposal. Essentially, these services constitute “sample asset management plus cold chain compliant operations.” The overall gross margin is approximately 48%.

The core demand for biological sample storage and processing comes from drug development, clinical trials, diagnostic development, and advanced therapies. Pharmaceutical companies and CROs increasingly outsource biobanking, cold chain management, sample logistics, and tracking to professional institutions, as any loss, uncontrolled freeze-thaw, or incomplete chain-of-custody records can directly impact clinical data quality and regulatory compliance.

Industry growth is driven not simply by an increase in sample quantity but by higher sample value. With the rise of oncology, immunology, rare diseases, companion diagnostics, cell therapies, and gene therapies, requirements for PBMCs, cells, tissues, RNA, viral vectors, and therapeutic-grade retained samples in terms of temperature zones, timing, viability, and traceability have significantly increased. The competitive landscape is concentrating around “global network + compliance capability + data systems.” Lower-end frozen storage faces regional competition and price pressure, while liquid nitrogen storage, GxP/GMP compliance, cell therapy, multinational clinical trial sample management, and high-value sample transfers remain high-barrier segments.

Over the next six years, the market is expected to grow from USD 6.1 billion in 2026 to USD 9.1 billion by 2031, driven primarily by more complex clinical trials, the industrialization of advanced therapies, digital sample management, and pharmaceutical outsourcing for cost reduction. Overall, this is a moderately sized professional life sciences service market with high client stickiness, strong compliance barriers, and stable gross margins.

This report presents a comprehensive overview of the global Biological Specimen Preservation & Handling market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Storage Only
  • Sample Processing
  • Inventory Management
  • Logistics Management
  • Full Service
  • Other Services

Segment by Storage Condition

  • Controlled Ambient
  • Refrigerated
  • Frozen
  • Ultra-Low
  • Cryogenic
  • Special Conditions

Segment by Specimen Form

  • Fluid Specimens
  • Analytical Tissue Specimens
  • Cell Specimens
  • Molecular Specimens
  • Microbial Specimens
  • Gross Anatomical Specimens
  • Other Specimens

Segment by Application

  • Drug R&D
  • Diagnostics
  • Medical Training
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Biological Specimen Preservation & Handling market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Drug R&D, Diagnostics, Medical Training evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Biological Specimen Preservation & Handling Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 8.7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$5.48B
2025
Forecast
$9.8B
2032
CAGR
8.7%
2025–2032
Gebieden
5
global
Key companies
Azenta Life SciencesThermo Fisher Scientific / Patheon / PPDLabcorpIQVIA LaboratoriesICON plcMedpacePrecision for MedicineCryoport Systems
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Storage OnlySample ProcessingInventory ManagementLogistics ManagementFull ServiceOther Services
By Application
Drug R&DDiagnosticsMedical TrainingOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Storage Only
  • 3.1.3 Sample Processing
  • 3.1.4 Inventory Management
  • 3.1.5 Logistics Management
  • 3.1.6 Full Service
  • 3.1.7 Other Services
  • 3.1.8 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Drug R&D
  • 4.1.3 Diagnostics
  • 4.1.4 Medical Training
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Azenta Life Sciences
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Thermo Fisher Scientific / Patheon / PPD
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Labcorp
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 IQVIA Laboratories
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 ICON plc
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Medpace
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Precision for Medicine
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Cryoport Systems
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 SciSafe
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Masy BioServices
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Sampled
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Eurofins Viracor BioPharma
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Cerba Research
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Clinigen
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Almac Group
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 CellCarta
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Frontage Laboratories
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 LabConnect
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 KCAS Bio
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Quest Diagnostics
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Charles River Laboratories
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 WuXi AppTec
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Parexel
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Sonic Clinical Trials
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 REPROCELL
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Astoriom
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 Cryosite
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 Discovery Life Sciences
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 BioIVT
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
  • 8.30 Boca Biolistics
  • 8.30.1 Company Overview
  • 8.30.2 Key Products & Segments
  • 8.30.3 Financial Performance (2023–2025)
  • 8.30.4 Business Strategy
  • 8.30.5 SWOT Analysis
  • 8.30.6 Strategic Implications (2026–2032)
  • 8.31 Cureline
  • 8.31.1 Company Overview
  • 8.31.2 Key Products & Segments
  • 8.31.3 Financial Performance (2023–2025)
  • 8.31.4 Business Strategy
  • 8.31.5 SWOT Analysis
  • 8.31.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Biological Specimen Preservation & Handling market?
The global Biological Specimen Preservation & Handling market is estimated at US$ 5.48 billion in 2025 (base year) and is projected to reach US$ 9.85 billion by 2032.
What is the forecast CAGR for the Biological Specimen Preservation & Handling market?
The market is expected to grow at a CAGR of 8.7% from 2026 to 2032, expanding from US$ 5.48 billion in 2025 to US$ 9.85 billion in 2032, roughly 1.8 times its base-year value.
What is Biological Specimen Preservation & Handling?
Biological sample storage and processing services refer to third-party services that manage human, animal, or microbial samples, providing end-to-end or modular workflows including sample receipt, identification registration, barcode tracking, pre-processing, aliquoting, refrigerated/frozen/ultra-low temperature/liquid nitrogen storage, inventory management, inbound and outbound logistics, transport, and eventual disposal.
How is the Biological Specimen Preservation & Handling market segmented by type?
By type, the market is segmented into Storage Only, Sample Processing, Inventory Management, Logistics Management, Full Service and Other Services.
What are the key applications of Biological Specimen Preservation & Handling?
Key applications covered include Drug R&D, Diagnostics, Medical Training and Others.
Which companies are profiled in the Biological Specimen Preservation & Handling market report?
Key players profiled include Azenta Life Sciences, Thermo Fisher Scientific / Patheon / PPD, Labcorp, IQVIA Laboratories, ICON plc, Medpace, Precision for Medicine and Cryoport Systems, among 31 companies covered in total.
What geographies does the Biological Specimen Preservation & Handling market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Biological Specimen Preservation & Handling?
Industry growth is driven not simply by an increase in sample quantity but by higher sample value.
What are the main risks and barriers in the Biological Specimen Preservation & Handling market?
The competitive landscape is concentrating around “global network + compliance capability + data systems.” Lower-end frozen storage faces regional competition and price pressure, while liquid nitrogen storage, GxP/GMP compliance, cell therapy, multinational clinical trial sample management, and high-value sample transfers remain high-barrier segments.
Who should buy the Biological Specimen Preservation & Handling market report?
The report is intended for manufacturers and solution providers, distributors and end users in Drug R&D, Diagnostics and Medical Training, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Biological Specimen Preservation & Handling market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.